Lykos Therapeutics
生物技术研究
San Jose，California 22,352 位关注者
Dedicated to transforming mental healthcare
At Lykos Therapeutics, our mission is to transform the way mental health is treated.
Meet Our Senior Leadership
Mission
Our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel investigational treatment options.
Learn MoreMDMA-Assisted Therapy (MDMA-AT)
MDMA-AT is an investigational treatment being studied using a combination of MDMA in conjunction with talk therapy to treat PTSD. MDMA is part of a class of drugs, entactogens, that produce experiences of emotional communion, oneness, relatedness, and emotional openness and may have potential use for various medical conditions. MDMA-AT has not been approved by any regulatory agency. The safety and efficacy of MDMA-assisted therapy have not been established for the treatment of PTSD.
Learn MoreResearch
We are committed to conducting research to determine the safety and efficacy of our investigational products with the potential to help address unmet needs in mental health. We have completed six Phase 2 and two Phase 3 trials for the treatment of PTSD in adults and submitted a new drug application (“NDA”) to the FDA for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes talk therapy, and other supportive services provided by a qualified HCP.
Learn More